Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc (NBIX) is a leading neuroscience-focused biopharmaceutical company developing innovative therapies for complex neurological, endocrine, and neuropsychiatric disorders. This comprehensive news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives driving the company's mission to address unmet medical needs.
Stay informed with verified updates spanning FDA decisions, clinical trial results, research collaborations, and market expansion efforts. Our curated news collection covers essential developments including movement disorder therapies like Ingrezza® for tardive dyskinesia, endocrine disorder treatments, and emerging pipeline candidates in neuropsychiatry.
Key focus areas include updates on late-stage clinical programs, partnership announcements with academic institutions, and analyses of therapeutic innovations targeting conditions from Huntington's disease chorea to congenital adrenal hyperplasia. All content is rigorously sourced to ensure accuracy and relevance for both professional investors and medical stakeholders.
Bookmark this page for centralized access to Neurocrine Biosciences' latest scientific advancements, financial disclosures, and treatment development progress. Check regularly for objective reporting on one of biopharma's most innovative neuroscience-focused enterprises.
Neurocrine Biosciences (NASDAQ: NBIX) presented a post‑hoc analysis from the Phase 3 KINECT 4 study showing that continuous treatment with INGREZZA 40 mg once daily produced rapid, sustained, clinically meaningful improvements in tardive dyskinesia (TD) over 48 weeks.
Key outcomes: mean AIMS total score change exceeded the minimally clinically important difference at all post‑baseline visits; 90% (18/20) of participants who completed 48 weeks on continuous 40 mg reached ≥50% AIMS improvement; patients who reduced from 80 mg to 40 mg showed similar benefit. Safety was consistent with the known profile, with most adverse events mild/moderate and the most common being sleepiness and tiredness. Findings were presented October 15–18, 2025 at the American Psychiatric Nurses Association conference.
Neurocrine Biosciences (NASDAQ: NBIX) will release its third quarter 2025 financial results and host a conference call and webcast on October 28, 2025. The press release is scheduled for 1:00 p.m. PT / 4:00 p.m. ET, followed by the conference call at 1:30 p.m. PT / 4:30 p.m. ET.
Dial-in numbers: Domestic 800-274-8461, International 203-518-9814 with Conference ID: NBIX. The webcast will be available on the company's Investors page at neurocrine.com, with a replay posted about one hour after the event and archived for ~one month.
Neurocrine Biosciences (Nasdaq: NBIX) announced on October 6, 2025 the appointment of Mike Sibley as Senior Vice President and General Manager of its Neuropsychiatry franchise.
Sibley will lead sales and marketing strategy for Neurocrine's neuropsychiatry products, including the INGREZZA franchise. He brings more than 20 years of commercial biopharma experience and joins after a nine-year tenure at Sanofi, most recently as General Manager for US Dermatology. Prior roles include positions at Galderma, J.P. Morgan Chase & Co., and Johnson & Johnson. Sibley holds a Bachelor of Arts in Economics from the University of Massachusetts, Amherst.
Neurocrine Biosciences (Nasdaq: NBIX) presented three-year open-label KINECT-HD2 data showing once-daily INGREZZA (valbenazine) produced early and sustained reductions in Huntington's disease chorea with an established long-term safety profile.
Key results: 154 adults treated up to 156 weeks; mean UHDRS Total Maximal Chorea improvement by Week 2 was -3.4±0.3 (n=146); PGI-C responders rose from 34.5% at Week 2 to 77.8% at Week 156. TEAEs were consistent with known safety: 97.4% reported ≥1 TEAE; most common were falls (42.9%), somnolence (25.3%), fatigue (21.4%); discontinuations due to TEAEs were 15.6%.
Neurocrine Biosciences (NASDAQ:NBIX) announced new post-hoc analysis data from their Phase 4 KINECT-PRO™ study of INGREZZA® (valbenazine) for tardive dyskinesia (TD) treatment. The study showed that 57.8% of patients (26 of 45) achieved symptomatic remission at Week 24, with success rates of 58.3% at 40mg, 44.4% at 60mg, and 62.5% at 80mg doses.
The analysis demonstrated significant improvements in patient-reported outcomes among those achieving remission, including enhanced quality of life and reduced disease burden. Notably, patients showed substantial improvements across multiple measures: the Tardive Dyskinesia Impact Scale (TDIS™), Sheehan Disability Scale (SDS), and EuroQoL Visual Analog Scale (EQ-VAS). The safety profile remained consistent with previous findings, with no new concerns identified.
[ "High remission rate of 57.8% achieved at Week 24 across different dosages", "Significant improvements in patient-reported outcomes and quality of life metrics", "Earlier achievement of TD symptom remission compared to previous studies", "Consistent safety profile with no new concerns identified" ]Neurocrine Biosciences (Nasdaq: NBIX) announced positive results from its Phase 2 SAVITRI™ study of osavampator (NBI-1065845) for major depressive disorder (MDD). The study demonstrated statistically significant improvements in depression severity at both Day 28 and Day 56 with 1 mg daily oral dosing.
The trial, involving 183 adults, tested two doses (1 mg and 3 mg) against placebo. The 1 mg dose achieved the primary endpoint with significant MADRS score reduction and showed superior results in treatment response and remission rates. Osavampator, a first-in-class selective AMPA-PAM, was well-tolerated with no serious adverse events, with headache and nasopharyngitis being the most common side effects.
Neurocrine Biosciences (Nasdaq: NBIX) will present new data from its Phase 2 SAVITRI study of osavampator at Psych Congress 2025. The study investigates osavampator as an adjunctive treatment for adults with major depressive disorder (MDD) who have inadequate response to oral antidepressants.
Following positive top-line results, the company initiated a Phase 3 registrational program in January 2025, comprising five active enrolling studies. The company will present multiple posters, with two selected as finalists for Psych Congress Poster Awards, focusing on osavampator's clinical improvements in depression severity and its mechanism as a selective AMPA-PAM.
Neurocrine Biosciences (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, has announced its participation in four major investor conferences this September. The company's leadership team, including CEO Kyle Gano, CFO Matt Abernethy, and other executives, will present at the Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird Global Healthcare Conference, and TD Cowen Novel Mechanisms Summit.
The presentations will be accessible via live webcasts on Neurocrine's website, with replays available for approximately one month. The company specializes in developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders, with FDA-approved treatments for conditions including tardive dyskinesia, Huntington's disease chorea, and endometriosis.
Neurocrine Biosciences (Nasdaq: NBIX) announced its participation in the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 8:00 a.m. ET. CEO Kyle Gano and VP of Investor Relations Todd Tushla will represent the company at the event.
The presentation will be accessible via live webcast on the company's investor relations website, with a replay available for approximately one month after the event. Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with FDA-approved treatments for various neurological conditions, including tardive dyskinesia, Huntington's disease chorea, and endometriosis.
Neurocrine Biosciences (NASDAQ:NBIX) reported strong Q2 2025 financial results with total net product sales of $682 million, representing 17% year-over-year growth. INGREZZA achieved Q2 net product sales of $624 million, while CRENESSITY contributed $53 million with 664 new patient enrollment start forms.
The company narrowed its 2025 INGREZZA net product sales guidance to $2.5-$2.55 billion from $2.5-$2.6 billion. Q2 GAAP net income was $107.5 million ($1.06 per share), compared to $65 million ($0.63 per share) in Q2 2024. The company maintains a strong balance sheet with $1.8 billion in cash and marketable securities.
Key developments include initiating Phase 3 trials for NBI-'568 in schizophrenia and advancing the pipeline in neuropsychiatry. The company has repurchased $168 million of common stock under its $500 million share repurchase program.
FAQ
What is the current stock price of Neurocrine Biosciences (NBIX)?
What is the market cap of Neurocrine Biosciences (NBIX)?
